The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma

被引：0

作者：

Raab, Marc-Steffen ^{[1
,2
]}

Orlowski, Robert ^{[3
]}

Richard, Shambavi ^{[4
]}

Grosicki, Sebastian ^{[5
]}

Takacs, Istvan ^{[6
]}

Strassz, Andras ^{[7
]}

Pahl, Andreas ^{[7
]}

Kulke, Michael ^{[7
]}

Michael, Thorsten ^{[7
]}

Last, Anette ^{[7
]}

Szaboki, Hajnalka ^{[7
]}

Jentsch, Garrit ^{[8
]}

Schoenborn-Kellenberger, Oliver ^{[9
]}

Kaufman, Jonathan L. ^{[10
]}

机构：

[1] Heidelberg Univ Hosp, GMMG Study Grp, Heidelberg, Germany

[2] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Med Univ Silesia, Katowice, Poland

[6] Semmelweis Univ, Dept Internal Med & Oncol, Budapest, Hungary

[7] Heidelberg Pharma AG, Heidelberg, Germany

[8] BAST GmbH, Heidelberg, Germany

[9] Cogitars, Heidelberg, Germany

[10] Emory Univ, Atlanta, GA 30322 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-60

引用

页码：S38 / S38

页数：1

共 50 条

[1] The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma
Kaufman, Jonathan
Raab, Marc
Richard, Shambavi
Grosicki, Sebastian
Takacs, Istvan
Strassz, Andras
Pahl, Andreas
Kulke, Michael
Michael, Thorsten
Last, Anette
Szaboki, Hajnalka
Jentsch, Garrit
Schonborn-Kellenberger, Oliver
Orlowski, Robert
CANCER RESEARCH, 2024, 84 (07)
[2] Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
Raab, Marc S.
Kaufman, Jonathan L.
Richard, Shambavi
Grosicki, Sebastian
Takacs, Istvan
Strassz, Andras
Pahl, Andreas Martin
Michael, Thorsten
Last, Anette
Szaboki, Hajnalka
Jentsch, Garrit
Schoenborn-Kellenberger, Oliver
Orlowski, Robert Z.
BLOOD, 2023, 142
[3] Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
Kaufman, Jonathan L.
Orlowski, Robert Z.
Strassz, Andras
Pahl, Andreas
Michaels, Thorsten
Last, Anette
Szaboki, Hajnalka
Jentsch, Garrit
Schoenborn-Kellenberger, Oliver
Raab, Marc-Steffen
BLOOD, 2022, 140 : 7235 - 7236
[4] Preclinical Evaluation of Hdp-101, a Novel Anti-BCMA Antibody-Drug Conjugate, in Multiple Myeloma
Ko, Jonathan
Breunig, Christian
Figueroa, Vianiuhini
Lehners, Nicola
Baumann, Anja
Palfi, Aniko
Mueller, Christoph
Lutz, Christian
Hechler, Torsten
Kulke, Michael
Mueller-Tidow, Carsten
Goldschmidt, Hartmut
Pahl, Andreas
Raab, Marc S.
BLOOD, 2017, 130
[5] A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma
Strassz, Andras
Raab, Marc S.
Orlowski, Robert Z.
Kulke, Michael
Schiedner, Gudrun
Pahl, Andreas
BLOOD, 2020, 136
[6] Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate
Hechler, Torsten
Palfi, Aniko
Mueller, Christoph
Lutz, Christian
Pahl, Andreas
Kulke, Michael
CANCER RESEARCH, 2017, 77
[7] HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Figueroa-Vazquez, Vianihuini
Ko, Jonathan
Breunig, Christian
Baumann, Anja
Giesen, Nicola
Palfi, Aniko
Mueller, Christoph
Lutz, Christian
Hechler, Torsten
Kulke, Michael
Mueller-Tidow, Carsten
Kraemer, Alwin
Goldschmidt, Hartmut
Pahl, Andreas
Raab, Marc S.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 367 - 378
[8] HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma
Pahl, Andreas
Ko, Jonathan
Breunig, Christian
Figueroa, Vianiuhini
Lehners, Nicola
Baumann, Anja
Palfi, Aniko
Mueller, Christoph
Lutz, Christian
Hechler, Torsten
Kulke, Michael
Mueller-Tidow, Carsten
Goldschmidt, Hartmut
Raab, Marc
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
Hans C. Lee
Noopur S. Raje
Ola Landgren
Vijay V. Upreti
Jin Wang
Ariel A. Avilion
Xuguang Hu
Erik Rasmussen
Gataree Ngarmchamnanrith
Hisaki Fujii
Andrew Spencer
Leukemia, 2021, 35 : 255 - 258
[10] Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy
Hau, Andrew
Zhu, Tong
Wang, Rengang
Lau, Megan
Li, Lingna
Li, Xiaoqing
Sun, Yingqing
Kovacs, Ernest
Khasanov, Alisher
Deng, Dalun
Yan, Zheng
Knight, Robert D.
Kaufmann, Gunnar F.
Ji, Henry
Li, Hui
Zhang, Hong
BLOOD, 2019, 134

← 1 2 3 4 5 →